$5.8M in CY2024 Part D spend16K claims · 3K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Efavirenz used for?
Efavirenz is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor medication tracked in Medicare Part D.
Is there a generic for Efavirenz?
Yes. 8 ANDAs filed at FDA, 5 generic manufacturers currently shipping.
How much does my plan pay for Efavirenz?
Across 329 Part D plans, Efavirenz averages $1.37/unit (NADAC). Lowest available: $1.37/unit. Highest in distribution: $1.37/unit.
Is Efavirenz on the FDA shortage list?
No. Efavirenz is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.